Ertapenem Susceptibility in Drug-Resistant Bacteria
Author Information
Author(s): Mody Rupal M, Erwin Daniel P, Summers Amy M, Carrero Hector A, Selby Edward B, Ewell Allesa J, Moran Kimberly A
Primary Institution: Walter Reed Army Medical Center
Hypothesis
Can imipenem susceptibility be used as a surrogate for ertapenem susceptibility in ESBL-producing organisms?
Conclusion
Ertapenem may be a viable alternative to other carbapenems for treating infections caused by ESBL-producing E. coli and K. pneumoniae, but further studies are needed.
Supporting Evidence
- 100% of ESBL isolates tested were susceptible to ertapenem.
- 100% of the same isolates were also susceptible to imipenem.
- Ertapenem offers once daily dosing, making it easier for patients.
Takeaway
This study found that all tested bacteria were sensitive to a new antibiotic called ertapenem, which could be easier to use than older antibiotics.
Methodology
100 ESBL isolates were tested for susceptibility using Vitek Legacy and E-test methods.
Potential Biases
Potential interobserver variability in interpreting E-test results.
Limitations
The study lacked resistant isolates and non-ESBL-producing controls.
Participant Demographics
Isolates were collected from clinical specimens at Walter Reed Army Medical Center.
Statistical Information
Confidence Interval
[95% CI 0.032 ug/mL for E. coli; 95% CI 0.070 for K. pneumoniae]
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website